AMGEN: Innovation + Emerging Market – A Balanced Approach!
Acquisition in 2012 of Micromet (MITI) and KAI pharma (pvt., US based) has boosted Amgen’s (AMGN) pipeline, while Mustafa Nevzat pharma (MN pharma, pvt., Turkey) is a strategic move to increase its presence in the growing emerging/ international markets. Data at ASCO ’12 increases confidence in its pipeline and acquisitions- Positive data of Blinatumomab (Pivotal PhII, rrALL), Rilotumomab (AMG 102, cMET/HGF Mab PhII, gastric Cancer), and denosumab (in subset CRPC pts). Denosumab is the key growth driver for next two to three year. What more upside, we expect from launched drugs and the pipeline… For more details, please read our report released on May 29th, 2012 on AMGN, titled “Innovation + Emerging Market – A Balanced Approach”
COMPANIES MENTIONED
AMGEN
AMGEN
